FDA Grants Breakthrough Therapy Designation to Sanofi's Tolebrutinib for Progressive MS

The U.S. Food and Drug Administration (FDA) has awarded Breakthrough Therapy designation to Sanofi's investigational drug, tolebrutinib, for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS). This designation signifies that the drug may offer substantial improvement over existing therapies for a serious condition.

The designation stems from positive data from the HERCULES Phase 3 clinical trial. The study indicated that tolebrutinib delayed the onset of confirmed disability progression by 31% compared to a placebo. Additionally, the trial showed nearly double the rate of confirmed disability improvement in patients treated with tolebrutinib compared to those on placebo.

Tolebrutinib is a brain-penetrant Bruton's tyrosine kinase (BTK) inhibitor, a class of drugs that target the immune system. This makes it the first and only BTK inhibitor for MS to receive Breakthrough Therapy status from the FDA. The condition nrSPMS is characterized by continuing disability accumulation without active relapses, representing a significant unmet medical need in multiple sclerosis treatment.

Regulatory submissions for tolebrutinib are currently being finalized for the U.S. and prepared for the European Union. Sanofi is also conducting the PERSEUS Phase 3 study for primary progressive multiple sclerosis, with results anticipated in the latter half of 2025. While the designation is encouraging, tolebrutinib is still under clinical investigation, and its safety and efficacy have not been fully evaluated or approved by any regulatory authority.